Altimmune Altimmune (ALT) stock soared last Friday after speculation of a takeover by three large companies. The speculation died today. Nevertheless, other news about this firm could be important, especially from Altimmune itself. The firm announced that it will assess the potential of GLP . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
AstraZeneca AstraZeneca (AZN) has positive high-level results from the MATTERHORN Phase III trial, which showed perioperative treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (
AstraZeneca and Daiichi Sankyo AstraZeneca (AZN) and Daiichi Sankyo’s (DSKYF) (trastuzumab deruxtecan) has been recommended for approval in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (AZN) product ENHERTU® (fam-trastuzumab deruxtecan-nxki) was approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low or HER2 ultralow breast cancer, as determined by an FDA-approved test, that has progressed on one . . . This content is for paid subscribers. Please click here …
AstraZeneca in the NEWS AstraZeneca (AZN) Phase III trial CAPItello-281, which combines Truqap (capivasertib), abiraterone, and androgen deprivation therapy (ADT), demonstrates statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) vs. abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer . . . This content is for paid subscribers. Please click here to subscribe or here to …
AstraZeneca Agreement with CSPC Pharmaceutical Group Yesterday, October 7, 2024, AstraZeneca (AZN) announced it entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
AstaZeneca Fasenra Approval AstraZeneca (AZN) product Fasenra (bevacizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) - a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. The approval in the United States FDA was based on positive results from the MANDARA Phase III trial published in . …
AstraZeneca Imfinzi + Imjudo Updated results from the HIMALAYA Phase III trial have demonstrated that AstraZeneca (AZN) Imfinzi (durvalumab) plus Imjudo (tremelimumab) showed a sustained clinically meaningful overall survival (OS) benefit at five years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. The results from HIMALAYA were presented at . . . …
US FDA Approval for AstraZeneca’s IMFINZI AstraZeneca (AZN): The trial results of the FDA newly approved combination products demonstrated a reduction in the risk of disease progression or death by 58% in patients with dMMR endometrial cancer versus chemotherapy alone. Endometrial cancer is the fourth most common cancer in women In the United States. More than 66,000 patients diagnosed and almost 12,000 deaths in …
Compugen's Soaring Stock Many recent events led to Compugen's (CGEN) soaring stock after a huge decline in its price. In spite of the tremendous stock decline, Prohost never doubted the fact that Compugen has solid scientific fundamentals and great scientists. The firm has done a great job utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological . . . …
Comprehensive Prohost Letter Issues Coronavirus Variant Omicron A lot has happened since the coronavirus variant Omicron was discovered in South Africa. After having been responsible for a severe plummeting of the stock market, Omicron boosted the market after being described by many scientists as fast spreading with different yet milder symptoms when compared to those caused by SARS-CoV-1, SARS-CoV-2 (the virus that causes COVID-19) and …
AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention AstraZeneca (AZN) product Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with the first doses expected to become available very soon. The EUA for Evusheld was granted for . . . This content is for paid subscribers. Please click here …
Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals (IONS) announced entering into a strategic collaboration agreement with AstraZeneca (
AstraZeneca Saphnelo Approved by Japanese Ministry of Health, Labor and Welfare Developed by AstraZeneca (AZN), Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus. The approval by the Japanese Ministry of Health, Labor and Welfare (MHLW) was based on efficacy and safety data from the Saphnelo clinical . . . This content is for paid subscribers. …
Cassava Sciences There is no doubt in our minds that Cassava Sciences’ (SAVA) product simufilam will play a major role in the treatment of Alzheimer’s disease. We have no doubt that simufilam has improved cognition in patients with mild to moderate Alzheimer’s disease. The cognition gained 3.0 Points on ADAS-Cog in 9 months. The Alzheimer’s patients’ disordered . . . This content is for paid …
AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85% AstraZeneca (AZN) and Amgen (
AstraZeneca: Tagrisso for Adult Patients with Early-Stage EGFRm NSCLC... AstraZeneca (AZN): Tagrisso (osimertinib) has been recommended for marketing authorization in the European Union for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. (CVAC), when the company announced business updates and financial results for its fourth quarter and full-year 2020. The reason for our interest was the fact that the U.S. was looking to take over this firm two years ago to no avail. A more important …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.